

DAFTAR PUSTAKA

- Aborehab, N.M., Elnagar, M.R., Waly, N.E., 2020. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. *J Biochem Mol Toxicol* 35(2):1-11.
- Al-Mahayri, Z.N., AlAhmad, M.M., Ali, B.R. 2021. Current opinion on the pharmacogenomics of paclitaxel-induced toxicity. *Expert Opin Drug Metab Toxicol* 17:7, 785-801.
- Al-Mulhim, F., Alqosaibi, A.I., Al-Muhna, A., Farid, K., Abdel-Ghany, S., Rizk, H., Prince A-B., Isichei, A., Sabit, H., 2021. CRISPR/Cas9-mediated activation of CDH1 supresses metastasis of breast cancer in rats. *Electron. J. Biotechnol* 53:54-60.
- Ali A, Ali A, Ahmad S. Alterations of Glutathione and GSTM1 Mutation Induce Tumor Metastasis and Invasion Via EMT Pathway in Breast Cancer Patients. *EJMO* 2021;5(3):249–259.
- Ali, A., Ayaz, A., Shafiq, A., 2021. Alteration of glutathione and GSTM1 mutations onduce tumor metastasis and invasion via EMT pathway in breast cancer patients. *Res Sq.* :1-18.
- Arakawa S. Utilization of glutathione S-transferase Mu 1- and Theta 1-null mice as animal models for absorption, distribution, metabolism, excretion and toxicity studies. *Expert Opin Drug Metab Toxicol*. 2013 Jun;9(6):725-36. doi: 10.1517/17425255.2013.780027. Epub 2013 Mar 18. PMID: 23506349.
- Arifin, W.N., & Zahirudddin, W.M., 2017. Sample Size Calculation in Animal Studies Using Resource Equation Approach. *Malays J Med Sci* 24(5);101-105.
- Arroyo-Crespo, J.J., Armiñán, A., Charbonnier, D., Deladriere, C., Palomino-Schätzlein, M., Lamas-Domingo, R., Forteza, J., Pineda-Lucena, A., Vicent, M.J., 2019. Characterization of triple-negative breast cancer preclinical models provides functional evidence of metastatic progression. *Int J Cancer* 145(8):2267-2281.
- Balseiro, C.S., Faro, C., Carvalho L. 2021. Metabolic pathways in sporadic colorectal carcinogenesis: A new proposal. *Med. Hypotheses* 148:1-11.
- Barbuti AM, Chen ZS. 2015. Paclitaxel Through the Ages of Anticancer Therapy: Exploring Its Role in Chemoresistance and Radiation Therapy. *Cancers (Basel)* 7(4):2360-71.
- Bhattacharjee, P. et al. Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2. *Sci. Rep.* 3, 2704; DOI:10.1038/srep02704 (2013)
- Caprette, D.R., 1996 Measuring Relative Mobility of Protein Bands Experimental Biosciences [serial online] [updated 2007 Jan 5] [cited 2022 Jun 19]; Available from: URL: www.ruf.rice.edu/~bioslabs/studies/sds-page/rf.html
- Chen D, Tang JX, Li B, Hou L, Wang X, Kang L. CRISPR/Cas9-mediated genome editing induces exon skipping by complete or stochastic altering splicing in

- the migratory locust. *BMC Biotechnol.* 2018 Sep 25;18(1):60. doi: 10.1186/s12896-018-0465-7. PMID: 30253761; PMCID: PMC6156852.
- Conant D, Hsiao T, Rossi N, Oki J, Maures T, Waite K, Yang J, Joshi S, Kelso R, Holden K, Enzmann BL, Stoner R. Inference of CRISPR Edits from Sanger Trace Data. *CRISPR J.* 2022 Feb;5(1):123-130. doi: 10.1089/crispr.2021.0113. Epub 2022 Feb 2. PMID: 35119294.
- Cristiello, C., Azim Jr, H.A., Schouten, P.C., Linn S.C., Sotiriou, C., 2012. Understanding the biology of triple-negative breast cancer. *Ann. Oncol* 23 Suppl 6:13-8.
- de Oliveira, A. L., Santos, R. E. d. , & Rodrigues, F. F. O. (2012). Chemotherapy and Mechanisms of Resistance in Breast Cancer. In (Ed.), *Neoadjuvant Chemotherapy - Current Applications in Clinical Practice*. IntechOpen. <https://doi.org/10.5772/24629>
- Diofano F, Weinmann K, Schneider I, Thiessen KD, Rottbauer W, Just S. Genetic compensation prevents myopathy and heart failure in an in vivo model of Bag3 deficiency. *PLoS Genet.* 2020 Nov 2;16(11):e1009088. doi: 10.1371/journal.pgen.1009088. PMID: 33137814; PMCID: PMC7605898.
- Doll NM, Gilles LM, Gérentes MF, Richard C, Just J, Fierlej Y, Borrelli VMG, Gendrot G, Ingram GC, Rogowsky PM, Widiez T. Single and multiple gene knockouts by CRISPR-Cas9 in maize. *Plant Cell Rep.* 2019 Apr;38(4):487-501. doi: 10.1007/s00299-019-02378-1. Epub 2019 Jan 25. PMID: 30684023.
- Edwardsen H, Brunsvig PF, Solvang H, Tsalenko A, Andersen A, Syvanen AC, Yakhini Z, Børresen-Dale AL, Olsen H, Aamdal S, Kristensen VN. 2010. SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance. *Pharmacogenomics J* 10(6):513-23.
- El-Brolosy MA, Stainier DYR. Genetic compensation: A phenomenon in search of mechanisms. *PLoS Genet.* 2017 Jul 13;13(7):e1006780. doi: 10.1371/journal.pgen.1006780. PMID: 28704371; PMCID: PMC5509088.
- El-Deek, S.E.M., Abdel-Ghany, S.M., Hana, R.S., Mohamed. A.A.R., El-Melegy, N.T., Sayed, A.A., 2021. Genetic polymorphism of lysyl oxidase, glutathione S-transferase M1, glutathione-S-transferase T1, and glutathione S-transferase P1 genes as risk factors for lung cancer in Egyptian patients. *Mol Biol Rep* 48(5):4221-32.
- Feng S, Wang Z, Li A, Xie X, Liu J, Li S, Li Y, Wang B, Hu L, Yang L and Guo T (2022) Strategies for High-Efficiency Mutation Using the CRISPR/ Cas System. *Front. Cell Dev. Biol.* 9:803252. doi: 10.3389/fcell.2021.803252
- Ferlini A, Rimessi P. Exon skipping quantification by real-time PCR. *Methods Mol Biol.* 2012;867:189-99. doi: 10.1007/978-1-61779-767-5_12. PMID: 22454062.
- Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. *Arch Physiol Biochem.* 2007 Oct-Dec;113(4-5):234-58. doi: 10.1080/13813450701661198. PMID: 18158646.
- Frandsen SK, Gehl J (2017) Effect of calcium electroporation in combination with metformin in vivo and correlation between viability and intracellular ATP

- level after calcium electroporation in vitro. *PLoS ONE* 12(7): e0181839. <https://doi.org/10.1371/journal.pone.0181839>
- Fukui, M., Choi, H.J., Wang, P., Zhu, B.T., 2021. Mechanism underlying resveratrol's attenuation of paclitaxel cytotoxicity in human breast cancer cells: Role of the SIRT1-FOXO1-HER3 signaling pathway. *Cancer Treat Res Commun.* 28:1-8.
- Giuliano CJ, Lin A, Girish V, Sheltzer JM. Generating Single Cell-Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9. *Curr Protoc Mol Biol.* 2019 Sep;128(1):e100. doi: 10.1002/cpmb.100. PMID: 31503414; PMCID: PMC6741428.
- Gote, V., Sharma, A. D., Pal, D. 2021. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells. *Int J Mol Sci.* 22(3):1-31.
- Haghighi, N., Doosti, A., Kiani, J., 2021. Evaluation of CRISPR/Cas9 System Effects on Knocking Out NEAT1 Gene in AGS Gastric Cancer Cell Line with Therapeutic Perspective. *J. Gastrointest. Cancer* :1-9.
- Hazafa, A., Mumtaz, M., Farooq, M.F., Bilal, S., Chaudhry, S.N., Firdous, M., Naeem H., Ullah M.O., Yameen, M., Mukhtiar, M.S., Zafar, F., 2020. CRISPR/Cas9: A powerful genome editing technique for the treatment of cancer cell with present challenges and future directions. *Life Sci* 263:1-14.
- Isaac RS, Jiang F, Doudna JA, Lim WA, Narlikar GJ, Almeida R. Nucleosome breathing and remodeling constrain CRISPR-Cas9 function. *Elife.* 2016 Apr 28;5:e13450. doi: 10.7554/eLife.13450. PMID: 27130520; PMCID: PMC4880442.
- Iwata S, Nakadai H, Fukushi D, Jose M, Nagahara M, Iwamoto T. Simple and large-scale chromosomal engineering of mouse zygotes via in vitro and in vivo electroporation. *Sci Rep.* 2019 Oct 11;9(1):14713. doi: 10.1038/s41598-019-50900-y. PMID: 31604975; PMCID: PMC6789149.
- Kallimasioti-Pazi EM, Thelakkad Chathoth K, Taylor GC, Meynert A, Ballinger T, Kelder MJE, et al. (2018) Heterochromatin delays CRISPR-Cas9 mutagenesis but does not influence the outcome of mutagenic DNA repair. *PLoS Biol* 16(12): e2005595. <https://doi.org/10.1371/journal.pbio.2005595>
- Kaneko, T., Sakuma, T., Yamamoto, T. & Mashimo, T. Simple knockout by electroporation of engineered endonucleases into intact rat embryos. *Sci. Rep.* 4, 6382; DOI:10.1038/srep06382 (2014)
- Kondrashov, A., 2021. The precise magic of CRISPR. *FEBS Open Bio* 11(6):1520-23.
- Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY. 2015. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. *Cancer Sci* 106(1):86-93.
- Kong, X., Li, Z., Li, X., 2016. GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta analysis. *Cancer Chemother Pharmacol* 78:1163-73.

- Kusano H, Ohnuma M, Mutsuro-Aoki H, Asahi T, Ichinosawa D, Onodera H, Asano K, Noda T, Horie T, Fukumoto K, Kihira M, Teramura H, Yazaki K, Umemoto N, Muranaka T, Shimada H. Establishment of a modified CRISPR/Cas9 system with increased mutagenesis frequency using the translational enhancer dMac3 and multiple guide RNAs in potato. *Sci Rep*. 2018 Sep 13;8(1):13753. doi: 10.1038/s41598-018-32049-2. PMID: 30214055; PMCID: PMC6137036.
- Li, G., Xu, D., Sun, J., Zhao, S., Zheng, D., 2020. Paclitaxel inhibits proliferation and invasion and promotes apoptosis of breast cancer cells by blocking activation of the PI3K/AKT signaling pathway. *Adv Clin Exp Med* 29(11):1337-45.
- Liu, X.Y., Jiang, W., Ma, D., Ge, L.P., Yang, Y.S., Gou, Z.C., Xu, X.E., Shao, Z.M., Jiang, Y.Z., 2020. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer. *Theranostics* 10(24):10940-56.
- López-Manzaneda S, Ojeda-Pérez I, Zabaleta N, García-Torralba A, Alberquilla O, Torres R, Sánchez-Domínguez R, Torella L, Olivier E, Mountford J, Ramírez JC, Bueren JA, González-Aseguinolaza G, Segovia JC. *In Vitro* and *In Vivo* Genetic Disease Modeling via NHEJ-Precise Deletions Using CRISPR-Cas9. *Mol Ther Methods Clin Dev*. 2020 Oct 15;19:426-437. doi: 10.1016/j.omtm.2020.10.007. PMID: 33294491; PMCID: PMC7683234.
- Ma Z, Chen J. Premature Termination Codon-Bearing mRNA Mediates Genetic Compensation Response. *Zebrafish*. 2020 May 20. doi: 10.1089/zeb.2019.1824. Epub ahead of print. PMID: 32434440.
- Miri, A., Kiani, E., Habibi, S., Khafaei M., 2021. Triple-negative breast cancer: biology, pathology, and treatment. *CAJMPSI* 2:81-96.
- Mehrgou, A. & Akouchekian, M., 2016. The importance of BRCA1 and BRCA2 genes mutation in breast cancer development. *MJIRI* 30(369):1-12.
- Mou H, Smith JL, Peng L, Yin H, Moore J, Zhang XO, Song CQ, Sheel A, Wu Q, Ozata DM, Li Y, Anderson DG, Emerson CP, Sontheimer EJ, Moore MJ, Weng Z, Xue W. CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion. *Genome Biol*. 2017 Jun 14;18(1):108. doi: 10.1186/s13059-017-1237-8. PMID: 28615073; PMCID: PMC5470253.
- Němcová-Fürstová, V., Kopperová, D., Balušíková, K., Ehrlichová, M., Brynychová, V., Václavíková, R., Daniel, P., Souček, P., Kovář, J., 2016. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. *Toxicol Appl Pharmacol* 310:215-28.
- Nissar, Saniya & A, Syed & Rasool, Roohi & Chowdri, Nisar & Rashid, Fouzia. (2017). Glutathione S Transferases: Biochemistry, Polymorphism and Role in Colorectal Carcinogenesis. *Journal of Carcinogenesis & Mutagenesis*. 08. 10.4172/2157-2518.1000287.
- Nteeba J, Ross JW, Perfield JW 2nd, Keating AF. 2013. High fat diet induced obesity alters ovarian phosphatidylinositol-3 kinase signaling gene expression. *Reprod Toxicol* 42:68-77.

- Ortega, M.A., Fraile-Martinez, O., Asunsolo, A., Bujan, J., Garcia-Honduvilla, N., Coca, S., 2020. Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. *J Oncol* :1-11.
- Pacholak, L.M., Kern, R., de Oliveira, S.T., Lúcio, L.C., Amarante, M.K., Guembarovski, R.L., Watanabe, M.A.E., Panis, C., 2021. Effects of GSTT1 and GSTM1 polymorphisms in glutathione levels and breast cancer development in Brazilian patients. *Mol Biol Rep* 48(1):33-40.
- Qin, W., Dion, S.L., Kutny, P.M., Zhang, Y., Cheng, A.W., Jillette, N.L., Malhotra, A., Geurts A.M., Chen, Y-G., Wang, H., 2015. Efficient CRISPR/Cas9-Mediated Genome Editing in Mice by Zygote Electroporation of Nuclease. *Genetics* 200:423-30.
- Rajagopal, T., Seshachalam, A., Rathnam, K.K., Jothi, A., Talluri, S., Venkatabalasubramanian, S., Dunna, N.R., 2021. Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women. *Breast Cancer Res Treat* 186(3):823-37.
- Ren, F., Ren, C., Zhang, Z., Duan, W., Lecourieux, D., Li, S., Liang, Z. 2019. Efficiency Optimization of CRISPR/Cas9-Mediated Targeted Mutagenesis in Grape. *Front. Plant Sci* 10:612.
- Ren, X., Zhao, B., Chang, H., Xiao, M., Wu, Y., Liu, Y., 2018. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signalling pathway in canine mammary gland tumor cells. *Mol. Med. Rep* 17:8289-99.
- Riss TL, Moravec RA, Niles AL, et al. Cell Viability Assays. 2013 May 1 [Updated 2016 Jul 1]. In: Markossian S, Grossman A, Brimacombe K, et al., editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004.
- Saghatelian, T., Tananyan, A., Janoyan, N., Tadevosyan, A., Petrosyan, H., Hovhannisyan, A., Hayrapetyan, L., Arustamyan, M., Arnhold, J., Rotmann, A-R., Hovhannisyan, A., Panossian, A. 2020. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial. *Phytomedicine* 70:1-19.
- Sakanyan V. (2018). Reactive Chemicals and Electrophilic Stress in Cancer: A Minireview. *High-throughput*, 7(2), 12.
- Scarf, I., Bierbaumer, L., Huber, H., Wittmann, P., Haider, C., Pirker, C., Berger, W., Mikulits, W., 2018. Dynamics of CRISPR/Cas9-mediated genomic editing of the AXL locus in hepatocellular carcinoma cells. *Oncol. Lett* 15:2441-50.
- Schrörs B, Boegel S, Albrecht C, Bukur T, Bukur V, Holtsträter C, Ritzel C, Manninen K, Tadmor AD, Vormehr M, Sahin U, Löwer M. Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. *Front Oncol*. 2020 Jul 23;10:1195. doi: 10.3389/fonc.2020.01195. PMID: 32793490; PMCID: PMC7390911.

- Si Y, Zhang Y, Ngo HG, Guan JS, Chen K, Wang Q, Singh AP, Xu Y, Zhou L, Yang ES, Liu XM. 2021. Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer. *Cancers (Basel)* 13(15):3749.
- Siegel, R.L., Miller, K.D., Fuchs, H.E., Jemal, A., 2021. Cancer Statistics, 2021. *CA Cancer J Clin* 71(1):7-33.
- Singh S, Joshi B, Saini A and Mohapatra T. Smoking, glutathione S transferase polymorphisms (GSTM1 & GSTT1) and their association with selected inflammatory biomarkers. *Al Ameen J Med Sci* 2022; 15(2): 113-122.
- Singhal, J., Chikara, S., Horne, D., Awasthi, S., Salgia, R., Sigal, S.S., 2021. Targeting RLIP with CRISPR/Cas9 controls tumor growth. *Carcinogenesis* 42(1):48-57.
- Sissung TM, Rajan A, Blumenthal GM, Liewehr DJ, Steinberg SM, Berman A, Giaccone G, Figg WD. 2019. Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. *PLoS One* 14(2):e0212097.
- Smith JL, Mou H, Xue W. Understanding and repurposing CRISPR-mediated alternative splicing. *Genome Biol.* 2018 Nov 6;19(1):184. doi: 10.1186/s13059-018-1565-3. PMID: 30400804; PMCID: PMC6219182
- Song Y, Yuan L, Wang Y, Chen M, Deng J, Lv Q, Sui T, Li Z, Lai L. Efficient dual sgRNA-directed large gene deletion in rabbit with CRISPR/Cas9 system. *Cell Mol Life Sci.* 2016 Aug;73(15):2959-68. doi: 10.1007/s00018-016-2143-z. Epub 2016 Jan 27. PMID: 26817461.
- Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. 2018. Genetic Markers in Triple-Negative Breast Cancer. *Clin Breast Cancer* 18(5):e841-e850.
- Sun, S., Wu, H., Wu, X., You, Z., Jiang, Y., Liang, X., Chen, Z., Zhang, Y., Wei, W., Jiang, Y., Chen, Y., Song, Y, Pang, D., 2021. Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer. *Front. Oncol* 11:1-11.
- Varan, G., Varan, C., Ozturk, S.C., Benito, J.M., Esendagli, G., Bilensoy, E., 2021. Therapeutic Efficacy and Biodistribution of Paclitaxel-Bound Amphiphilic Cyclodextrin Nanoparticles: Analyses in 3D Tumor Culture and Tumor-Bearing Animals In Vivo. *Nanomaterials* 11(515):1-17.
- Vasudevan V, Ramprasath T, Sampathkumar K, Puhari SSM, Yuvaraj S, Selvam GS. 2020. GSTM1-null allele predicts rapid disease progression in nondialysis patients and mortality among South Indian ESRD patients. *Mol Cell Biochem* 469(1-2):21-28.
- Weaver, B.A., 2014. How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell* 25(18):2677-81.
- Wu, C.L, Liu, J.F., Liu, Y., Wang, Y.X., Fu, K.F., Yu, X.J., Pu, Q., Chen, X.X., Zhou, L.J., 2019. Beclin1 inhibition enhances paclitaxel-mediated cytotoxicity in breast cancer in vitro and in vivo. *Int J Mol Med* 43(4):1866-78.
- Xia, A.L., He, Q.F., Wang, J.C., Zhu, J., Sha, Y.Q., Sun, B., Lu, X.J., 2018. Applications and advances of CRISPR-Cas9 in cancer immunotherapy. *J Med Genet* 56(1):4-9.

- Xiong, K., Zhang, Y., Wen, Q., Luo, J., Lu, Y., Wu, Z., Wang, B., Chen, Y., Zhao, L., Fu, S., 2020. Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy. *Int J Pharm* 589:1-11.
- Xue C, Greene EC. DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing. *Trends Genet.* 2021 Jul;37(7):639-656. doi: 10.1016/j.tig.2021.02.008. Epub 2021 Apr 22. PMID: 33896583; PMCID: PMC8187289.
- Yamaguchi H, Hishinuma T, Endo N, Tsukamoto H, Kishikawa Y, Sato M, Murai Y, Hiratsuka M, Ito K, Okamura C, Yaegashi N, Suzuki N, Tomioka Y, Goto J. 2006. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. *Int J Gynecol Cancer* 16(3):979-85.
- Yang H, Ren S, Yu S, Pan H, Li T, Ge S, Zhang J, Xia N. Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks. *Int J Mol Sci.* 2020 Sep 4;21(18):6461. doi: 10.3390/ijms21186461. PMID: 32899704; PMCID: PMC7555059.
- Yin L, Duan JJ, Bian XW, Yu SC. 2020. Triple-negative breast cancer molecular subtyping and treatment progress. *Breast Cancer Res* 22(1):61.
- Yu KD, Fan L, Di GH, Yuan WT, Zheng Y, Huang W, Chen AX, Yang C, Wu J, Shen ZZ, Shao ZM. Genetic variants in GSTM3 gene within GSTM4-GSTM2-GSTM1-GSTM5-GSTM3 cluster influence breast cancer susceptibility depending on GSTM1. *Breast Cancer Res Treat.* 2010 Jun;121(2):485-96. doi: 10.1007/s10549-009-0585-9. Epub 2009 Oct 24. PMID: 19856098.
- Zhang G, Qian X, Ren C, Wen L, Lyu H, Liao N. 2019. GSTM1 polymorphism in Oncotype DX assay is a potential predictive factor for taxane-based neoadjuvant chemotherapy in estrogen receptor-positive Chinese breast cancer patients. *Transl Cancer Res* 8(2):655-663.
- Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target Effects in CRISPR/Cas9-mediated Genome Engineering. *Mol Ther Nucleic Acids.* 2015 Nov 17;4(11):e264. doi: 10.1038/mtna.2015.37. PMID: 26575098; PMCID: PMC4877446.
- Zhang, W-P., He, X-F., Ye, X-H., 2020. Association between the combined effects of GSTM1 present/null and CYP1A1 MspI polymorphisms with lung cancer risk: an updated meta-analysis. *Biosci. Rep* 40(9):1-15.
- Zhou J, Wang J, Shen B, Chen L, Su Y, Yang J, Zhang W, Tian X, Huang X. Dual sgRNAs facilitate CRISPR/Cas9-mediated mouse genome targeting. *FEBS J.* 2014 Apr;281(7):1717-25. doi: 10.1111/febs.12735. Epub 2014 Feb 26. PMID: 24494965.